FDA Issues Warning to Curaleaf for 'Unsubstantiated' CBD Health Claims
ruggedcoast/Adobe Stock

FDA Issues Warning to Curaleaf for 'Unsubstantiated' CBD Health Claims

The warning letter included some examples of how Curaleaf Hemp products have been marketed on the company's social media accounts.

Subscribe
July 24, 2019

(CNN) In a move to crack down on the marketing of cannabis-related products, the US Food and Drug Administration has issued a warning letter to the company Curaleaf for selling some unapproved cannabidiol products with "unsubstantiated" health claims that the products treat cancer and Parkinson's disease, among other health conditions.

"Selling unapproved products with unsubstantiated therapeutic claims -- such as claims that CBD products can treat serious diseases and conditions -- can put patients and consumers at risk by leading them to put off important medical care. Additionally, there are many unanswered questions about the science, safety, effectiveness and quality of unapproved products containing CBD," Dr. Ned Sharpless, acting FDA commissionersaid in the agency's news release on Tuesday.

The warning letter, sent on Monday, included some examples of how Curaleaf Hemp products have been marketed on the company's social media accounts. 

Read more